|
Circularity Healthcare, maker of D’OXYVA®, the only proprietary microcirculatory and transdermal delivery system of its kind with breakthrough clinical evidence is announcing one of its first international product and branded website launch with Eulogiums Co. LTD. in Taiwan in February, 2016 (PRWEB) January 14, 2016 (Read article on PRWeb.com: http://www.prweb.com/releases/launch-taiwan/circularity-eulogiums/prweb13162945.htm) Circularity is launching a unique business model focused on consumers that it has developed and validated in the past three years through in-depth talks with hundreds of leading healthcare professionals in the United States and many strategically influential countries in most regions of the world. The Taiwanese website, http://www.doxyvataiwan.com is being followed by Circularity's upcoming European launch with the same platform and model in various languages, including German, French, Dutch, and Spanish. Circularity is aiming to make D’OXYVA® widely available across Europe and Asia in the first quarter of 2016. "Based on exceptionally positive feedback at professional events in Surabaya, Indonesia and Cebu, the Philippines and nearly a year of international business development in over sixty countries, we are extremely enthusiastic to launch across Asia with a start in Taiwan. Eulogiums possesses the kind of diversified portfolio Circularity is seeking in a partner to cover the broadest possible markets where D’OXYVA® can play a leading role", said Norbert Kiss, Circularity Healthcare President & CEO. "Eulogiums is very enthusiastic to launch D’OXYVA® in Taiwan with leading health professionals and institutions and adopt the unique business model developed by Circularity Healthcare after months of exceptional results during the initial pre-launch phase. The new initiative will allow us to serve the millions of people in great need of highly effective, affordable, fast, non-invasive, and pain-free solutions that harness and boost the body's own abilities to combat serious health complications and significantly increase quality of life while catering to the aesthetic and dermatology markets", said H.B. Chen, Eulogiums General Manager (Pharmacist). Eulogiums Medical Group was founded in 1987 and is headquartered in Taipei, Taiwan. The company has over twenty years of marketing experience in the Taiwanese orthopedic field. It offers a broad range of orthopedic devices and related products with advanced technology. It possesses strong knowledge and experience in product registration with regulatory authorities. It has obtained a strong OEM partnership experience, strong coordinating skills in project management, solid regional networks, and good relationships with key surgeons and doctors in a variety of medical fields. It is starting to gain considerable experience in the consumer products market with one of Asia's leading energy health drinks, Lipovitan®. Eulogiums' vision is to increase product diversification and market share; extend its network beyond its existing base of hospitals and purchasing agents; provide total solutions and comprehensive products based on patients' needs; and engage global markets. About Circularity Healthcare Circularity Healthcare, LLC, headquartered in Los Angeles, U.S.A. is an emerging world leader in proprietary circulatory health and non-invasive delivery technologies, committed to helping improve lives by developing, manufacturing, and marketing consumer health and wellness products. Circularity specializes in groundbreaking non-invasive technologies for highly portable medical gas-powered transdermal delivery systems and is pursuing regulatory approvals worldwide for device usage as treatment of a host of disease states. About Eulogiums Co. LTD. Eulogiums Medical Group was founded in 1987 and is headquartered in Taipei, Taiwan. The company has over twenty years of marketing experience in the Taiwanese orthopedic field. It offers a broad range of orthopedic devices and related products with advanced technology. It is starting to gain considerable experience in the consumer products market with one of Asia's leading energy health drinks, Lipovitan®. For More Information Please visit our corporate website at http://www.circularityhealthcare.com or our ecommerce website at http://www.doxyva.com and send your general inquiries via the Contact Us page, or for specific inquiries contact Circularity Public Relations at pr(at)circularityhealthcare(dot)com or by phone toll free at 1-855-5DOXYVA or at 1-626-817-6685 or 1-626-244-8090. Forward-Looking Information This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of Circularity Healthcare, LLC, its resources, progress in development, demand, and market outlook for non-invasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and Circularity Healthcare, LLC assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. Circularity Healthcare, LLC makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release. |